BiotechTube

Ketamine + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autism Spectrum Disorder

Conditions

Autism Spectrum Disorder

Trial Timeline

Dec 22, 2015 → May 7, 2018

NCT ID
NCT02611921

About Ketamine + Placebo

Ketamine + Placebo is a phase 1 stage product being developed by Roivant Sciences for Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02611921. Target conditions include Autism Spectrum Disorder.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02611921Phase 1Completed

Competing Products

20 competing products in Autism Spectrum Disorder

See all competitors
ProductCompanyStageHype Score
Cord Tissue Mesenchymal Stromal CellsCryo-CellPhase 2
44
Suramin SodiumPaxMedicaPhase 2
44
NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group + NORSPAN Buprenorphine Transdermal Patchs for Lower dose group + NORSPAN Buprenorphine Transdermal Patchs for higher dose groupShionogiPre-clinical
23
Lurasidone 20 mg daily + Lurasidone + PlaceboSumitomo PharmaPhase 3
77
Cariprazine + PlaceboAbbViePhase 3
77
CariprazineAbbViePhase 1
33
Omalizumab Injection [Xolair]NovartisPhase 1
33
RO7017773RochePhase 1
33
Placebo + RO7017773RochePhase 2
52
BalovaptanRochePhase 1
33
BalovaptanRochePhase 1
33
Balovaptan + EsomeprazoleRochePhase 1
33
Placebo + RG7314RochePhase 2
52
Placebo + RO5285119RochePhase 2
52
Balovaptan + PlaceboRochePhase 3
77
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
76
AripiprazoleBristol Myers SquibbPhase 2
51
KarXT + KarX-EC + KarXT + KarX-EC Matching PlaceboBristol Myers SquibbPhase 3
76
Brexpiprazole + PlaceboLundbeckPhase 3
74
BrexpiprazoleLundbeckPhase 3
74

Other Products from Roivant Sciences

Gimsilumab + PlaceboPhase 2
49